Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects

Hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, is used as an antitumor drug alone and together with conventional chemotherapeutics or radiation therapy. HU is used primarily to treat myeloproliferative diseases because it inhibits the enzyme ribonucleotide reductase involve...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Gang, Hardy, Micael, Topchyan, Paytsar, Zander, Ryan, Volberding, Peter, Cui, Weiguo, Kalyanaraman, Balaraman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215227/
https://www.ncbi.nlm.nih.gov/pubmed/34189437
http://dx.doi.org/10.1016/j.isci.2021.102673

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8215227/
https://www.ncbi.nlm.nih.gov/pubmed/34189437
http://dx.doi.org/10.1016/j.isci.2021.102673

Ejemplares similares